,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['destiny,breast,4', 'breast', 'destiny-breast04']
we published this paper around er/her2 co expression in 2014 and below is part of the discussion. what we thought of as research back then is now part of breast practice with the remarkable destiny-breast04 #asco2022 
Breast Oncologist. Endocrine Resistance, triple + BC, Breast CA in men. Stanford, Baylor, Markey, Jordan. Life revolves around my 2 boys.